Cargando…

Re: Factors affecting recurrence and progression of high grade non invasive bladder cancer treated by intravesical BCG

Detalles Bibliográficos
Autores principales:	Huang, Haichao, Jin, Jie, Li, Xin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Professional Medical Publicaitons 2014
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4320746/ https://www.ncbi.nlm.nih.gov/pubmed/25709643 http://dx.doi.org/10.12669/pjms.306.6408

Ejemplares similares

Factors effecting recurrence and progression of high grade non invasive bladder cancer treated by intravesical BCG
por: Kashif Khan, Muhammad, et al.
Publicado: (2014)

The use of intravesical BCG in urothelial carcinoma of the bladder
por: Alhunaidi, Omar, et al.
Publicado: (2019)

Systemic BCG‐osis following intravesical BCG instillation for bladder carcinoma
por: Liaw, Frank, et al.
Publicado: (2017)

Hyperthermic Intravesical Chemotherapy for BCG Unresponsive Non-Muscle Invasive Bladder Cancer Patients
por: de Jong, Joep J., et al.
Publicado: (2018)

A retrospective analysis of patients treated with intravesical BCG for high-risk nonmuscle invasive bladder cancer
por: Joshua, Julie Mariam, et al.
Publicado: (2019)

Intravesical BCG treatment causes a long-lasting reduction of recurrence and progression in patients with high-risk non-muscle-invasive bladder cancer
por: Thiel, Tomas, et al.
Publicado: (2018)

Disseminated BCG: Complications of Intravesical Bladder Cancer Treatment
por: To, Uyen, et al.
Publicado: (2014)

Treatment efficacy and tolerability of intravesical Bacillus Calmette-Guerin (BCG) - RIVM strain: induction and maintenance protocol in high grade and recurrent low grade non-muscle invasive bladder cancer (NMIBC)
por: Farah, Naim B, et al.
Publicado: (2014)

Prognostic value of impaired estimated glomerular filtration rate in intravesical BCG-treated non–muscle-invasive bladder cancer patients
por: Tae, Bum Sik, et al.
Publicado: (2017)

Bladder Sparing Therapy for BCG Failures – I – Intravesical Immunotherapy
por: Messing, Edward M.
Publicado: (2017)

Mycobacteria Bovis osteomyelitis following intravesical BCG for bladder cancer
por: Seegobin, Karan, et al.
Publicado: (2017)

High-Risk Non-Muscle-Invasive Bladder Cancer—Therapy Options During Intravesical BCG Shortage
por: Veeratterapillay, Rajan, et al.
Publicado: (2016)

Emerging concepts and spectrum of renal injury following Intravesical BCG for non-muscle invasive bladder cancer
por: Mohammed, Azharuddin, et al.
Publicado: (2017)

Predictive Markers for the Recurrence of Nonmuscle Invasive Bladder Cancer Treated with Intravesical Therapy
por: Miyata, Yasuyoshi, et al.
Publicado: (2015)

Autophagy Controls BCG-Induced Trained Immunity and the Response to Intravesical BCG Therapy for Bladder Cancer
por: Buffen, Kathrin, et al.
Publicado: (2014)

Asymptomatic renal BCG granulomatosis: An unusual complication of intravesical BCG therapy for carcinoma urinary bladder
por: Bhat, Suresh, et al.
Publicado: (2015)

Bacillus Calmette-Guérin Spondylodiscitis after Intravesical BCG Therapy: A Case Report
por: Kawai, Akihito, et al.
Publicado: (2022)

Intravesical bacillus Calmette-Guerin (BCG) in treating non-muscle invasive bladder cancer—analysis of adverse effects and effectiveness of two strains of BCG (Danish 1331 and Moscow-I)
por: Thyavihally, Yuvaraja B., et al.
Publicado: (2022)

Intravesical BCG in patients with non-muscle invasive bladder cancer induces trained immunity and decreases respiratory infections
por: van Puffelen, Jelmer H, et al.
Publicado: (2023)

Discriminators of mouse bladder response to intravesical Bacillus Calmette-Guerin (BCG)
por: Saban, Marcia R, et al.
Publicado: (2007)

Mycobacterial Osteomyelitis of the Spine Following Intravesical BCG Therapy for Bladder Cancer
por: Mackel, Charles E, et al.
Publicado: (2016)

Role of Intravesical BCG as a Therapeutic Vaccine for Treatment of Bladder Carcinoma
por: Doroud, Delaram, et al.
Publicado: (2022)

Systemic BCG-Osis as a Rare Side Effect of Intravesical BCG Treatment for Superficial Bladder Cancer
por: Lukacs, S., et al.
Publicado: (2013)

P58. Can T-cells predict response to intravesical BCG immunotherapy in high-risk non-invasive bladder cancer
por: Jallad, S, et al.
Publicado: (2014)

Correction: Intravesical BCG in patients with non-muscle invasive bladder cancer induces trained immunity and decreases respiratory infections
Publicado: (2023)

Clarification of Bladder Cancer Disease States Following Treatment of Patients with Intravesical BCG
Publicado: (2015)

Intravesical ALT-803 for BCG-unresponsive Bladder Cancer – A Case Report
por: Huang, Jeffrey, et al.
Publicado: (2017)

Multisystemic BCGitis: A rare complication of intravesical BCG immunotherapy for bladder cancer
por: Vilares, Ana T., et al.
Publicado: (2022)

Rapamycin enhances BCG-specific γδ T cells during intravesical BCG therapy for non-muscle invasive bladder cancer: a randomized, double-blind study
por: Ji, Niannian, et al.
Publicado: (2021)

Pott's disease post intravesical BCG
por: Jain, Anika
Publicado: (2023)

Intravesical Ty21a Treatment of Non–muscle-invasive Bladder Cancer Shows a Good Safety Profile
por: Lucca, Ilaria, et al.
Publicado: (2022)

Radical Cystectomy Against Intravesical BCG for High-Risk High-Grade Nonmuscle Invasive Bladder Cancer: Results From the Randomized Controlled BRAVO-Feasibility Study
por: Catto, James W. F., et al.
Publicado: (2021)

Development of a dynamic risk system for predicting the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer after thulium laser resection of bladder tumor or transurethral resection of bladder tumor followed by intravesical BCG instillation
por: Sun, Jian-Xuan, et al.
Publicado: (2023)

Association Between Antibiotic Treatment and the Efficacy of Intravesical BCG Therapy in Patients With High-Risk Non-Muscle Invasive Bladder Cancer
por: Pak, Sahyun, et al.
Publicado: (2021)

Pott’s Disease Caused by Mycobacterium bovis Following Intravesical BCG Therapy for Bladder Cancer
por: Jones, Zachary, et al.
Publicado: (2017)

Mycotic aortic aneurysms post-Intravesical BCG treatment for early-stage bladder carcinoma
por: Wadhwani, Aman, et al.
Publicado: (2018)

Novel intravesical bacterial immunotherapy induces rejection of BCG-unresponsive established bladder tumors
por: Moreo, Eduardo, et al.
Publicado: (2022)

Haemophagocytic lymphohistiocytosis after intravesical BCG administration for bladder cancer presenting with multiorgan failure
por: Liatsos, G. D., et al.
Publicado: (2023)

Efficacy of Bladder Intravesical Chemotherapy with Three Drugs for Preventing Non-Muscle-Invasive Bladder Cancer Recurrence
por: Zhang, Jianglei, et al.
Publicado: (2021)

Compared Efficacy of Adjuvant Intravesical BCG-TICE vs. BCG-RIVM for High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC): A Propensity Score Matched Analysis
por: Del Giudice, Francesco, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_27vhiaqr6pl7u80mh31bilrgnm